PCAR just delivered its strongest week in months, with the stock jumping 9.5% to $138.21 — and the catalyst is straightforward: quarterly results released Tuesday afternoon triggered an immediate re-rating from the Street's most influential voices.
The analyst response to the print was swift and directional. JP Morgan's Tami Zakaria raised her price target to $164 from $155 just this morning, maintaining Overweight — the third target lift from the firm in less than three months. That $164 target now sits roughly 19% above the current price, making it the most constructive published figure on the stock. Morgan Stanley moved in the same direction last week, nudging its Equal-Weight target to $113 from $109, though that figure sits well below the current price and implies the firm sees the recent move as having run ahead of fundamentals. The mean target across the Street is $137.59, almost exactly where the stock traded before this week's move — which means the consensus, in aggregate, has been caught slightly flat-footed by the rally. Most active analyst coverage points to a broadly positive but divided picture: bulls cite PACCAR's parts business resilience and strong North American truck demand; bears flag slowing global heavy truck production, tariff-related margin drag, and ongoing manufacturing realignment costs heading into 2027 EPA compliance cycles.
Positioning in the lending market offers essentially no signal here — this is simply not a stock that short sellers find interesting. Short interest is running at just 2.8% of the free float, down about 1.4% on the week as some bears covered into the earnings move. Borrowing costs are negligible at 0.49%, and availability is extraordinarily loose at over 2,500% — meaning shares to borrow vastly outnumber those already shorted. There is no squeeze dynamic, no borrow pressure, and no meaningful directional signal from the short side. Options positioning tells a more interesting story. The put/call ratio has dropped to 0.48, nearly a full standard deviation below its 20-day average of 0.65, reflecting a clear tilt toward calls after the print. That's a sharp reversal from late June and early July, when the PCR was consistently running above 1.0 — that earlier defensive positioning has been unwound almost entirely in the past two weeks of upward price action.
Valuation has moved meaningfully with the stock. The trailing P/E has expanded to 21.2x, up roughly 2 points over the past month, and price-to-book is at 3.4x — both reflecting the re-rating rather than any fundamental earnings acceleration. EV/EBITDA is near 20.6x. Factor scores paint a mixed picture: the dividend score ranks in the 78th percentile, EPS momentum over 30 days scores a solid 65, and the EPS surprise rank sits at 60. Value metrics are less flattering — the EV/EBIT rank is in the 28th percentile, and the days-to-cover rank is just 22. The ORTEX short score of 37.9 is stable and low, consistent with the absence of short-side pressure. Among correlated peers, WAB stands out with a 16% weekly gain — outpacing even PCAR's strong week — while ITW and FLS each rose around 8-9%. PH lagged the group at just 3.3%, suggesting the earnings-driven names carried the week's industrial rally.
The key question heading into August is whether the Street's consensus target — still clustered near $137-$138 — gets revised upward materially in the coming days as remaining analysts update models on the Q2 print. JP Morgan's $164 target is currently an outlier; how quickly the rest of the sell-side closes that gap will determine whether this week's move marks the beginning of a broader re-rating or an overshoot that consolidates.
See the live data behind this article on ORTEX.
Open PCAR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
